King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
14:16
Strong explosion at a warehouse of a company in Bulgaria that supplies ammunition to Ukraine
14:15
The Competition Council is investigating the market for printers and surveillance cameras.
14:02
Marius Lazurcă, the president's advisor on security issues, will make a visit to Turkey for discussions with high-ranking officials.
13:57
UEFA, CONCACAF and AFC have issued an open letter accusing FIFA of a breach of trust, following plans to sell a stake in the World Cup.
13:57
The Ministry of National Defense organizes MOBEX mobilization exercises in September
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
